Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Over $1M Bet On Stronghold Digital Mining? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Published 25/04/2023, 13:06
© Reuters.  Over $1M Bet On Stronghold Digital Mining? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
SDIG
-

Benzinga - The Dow Jones closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Stronghold Digital Mining

  • The Trade: Stronghold Digital Mining, Inc. (NASDAQ: SDIG) CEO Gregory A Beard acquired a total 1,241,555 shares an average price of $0.93. To acquire these shares, it cost around $1.15 million.
  • What’s Happening: Stronghold Digital Mining entered into $10 million private placement to fund purchase of bitcoin miners.
  • What Stronghold Digital Mining Does: Stronghold Digital Mining Inc is a vertically integrated crypto asset mining company currently focused on mining Bitcoin.
Ault Alliance
  • The Trade: Ault Alliance, Inc. (NYSE: AULT) Executive Chairman Milton C. Ault III acquired a total of 480,000 shares at an average price of $0.10. The insider spent around $49.22 to buy those shares.
  • What’s Happening: Ault Alliance recently announced a share buyback of up to 333,333,333 shares of common stock at $0.15 per sare through an exchange offer for a new class of preferred stock.
  • What Ault Alliance Does: Ault Alliance Inc is a diversified holding company.
Avalo Therapeutics
  • The Trade: Avalo Therapeutics, Inc. (NASDAQ: AVTX) 10% owner Caissa Capital Management Ltd acquired a total of 17,500 shares at an average price of $3.07. To acquire these shares, it cost around $53.67 thousand.
  • What’s Happening: Avalo Therapeutics, said on Apr. 20, it delivered written notice to Cantor Fitzgerald, RBC Capital Markets to terminate sales agreement.
  • What Avalo Therapeutics Does: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Check This Out: Top 5 Energy Stocks That Could Blast Off In April

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.